Latest & greatest articles for heart failure

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heart failure or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heart failure and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heart failure

241. Quality of life and long‐term mortality in patients with advanced chronic heart failure treated with intermittent low‐dose intravenous inotropes in an outpatient setting

Quality of life and long‐term mortality in patients with advanced chronic heart failure treated with intermittent low‐dose intravenous inotropes in an outpatient setting 28451448 2018 11 13 2055-5822 4 2 2017 May ESC heart failure ESC Heart Fail Quality of life and long-term mortality in patients with advanced chronic heart failure treated with intermittent low-dose intravenous inotropes in an outpatient setting. 122-129 10.1002/ehf2.12114 There are limited data on the effect of low-dose (...) , intermittent inotropic therapy in an outpatient setting on the quality of life (QOL) in patients with advanced refractory heart failure (HF) symptoms. We aimed to analyse the effect of this treatment modality on QOL and subsequent survival. The study population comprised 287 consecutive patients with advanced refractory HF symptoms who were treated with low-dose, intravenous intermittent inotropic therapy in the HF Day Care Service at Sheba Medical Centre between September 2000 and September 2012. All

ESC heart failure2016 Full Text: Link to full Text with Trip Pro

242. Antiplatelet versus anticoagulation treatment for patients with heart failure in sinus rhythm.

Antiplatelet versus anticoagulation treatment for patients with heart failure in sinus rhythm. BACKGROUND: Morbidity in patients with chronic heart failure is high, and this predisposes them to thrombotic complications, including stroke and thromboembolism, which in turn contribute to high mortality. Oral anticoagulants (e.g. warfarin) and antiplatelet agents (e.g. aspirin) are the principle oral antithrombotic agents. Many heart failure patients with sinus rhythm take aspirin because coronary artery (...) disease is the leading cause of heart failure. Oral anticoagulants have become a standard in the management of heart failure with atrial fibrillation. However, a question remains regarding the appropriateness of oral anticoagulants in heart failure with sinus rhythm. This update of a review previously published in 2012 aims to address this question. OBJECTIVES: To assess the effects of oral anticoagulant therapy versus antiplatelet agents for all-cause mortality, non-fatal cardiovascular events and risk of major

Cochrane2016

243. Sexual function of patients with heart failure: facts and numbers

Sexual function of patients with heart failure: facts and numbers 28217306 2018 11 13 2055-5822 4 1 2017 Feb ESC heart failure ESC Heart Fail Sexual function of patients with heart failure: facts and numbers. 3-7 10.1002/ehf2.12108 Approximately 60% to 87% of patients with heart failure (HF) report sexual problems, and numbers as low as 31% of HF patients younger than 70 have normal sexual function. When compared with healthy elders, the amount of perceived sexual dysfunction might be similar (...) (around 56%), but patients with HF are reporting more erectile dysfunction (ED) and also perceive that their HF symptoms (20%) or HF medication (10%) is the cause for their problems. The prevalence of ED is highly prevalent in men with cardiac disease and reported in up to 81% of cardiac patients, compared with 50% in the general older population. In total 25-76% of women with HF report sexual problems or concerns. The physical effort related to sexual activity in cardiac patients can be compared

ESC heart failure2016 Full Text: Link to full Text with Trip Pro

244. Cocoa flavanols reduce N-terminal pro-B-type natriuretic peptide in patients with chronic heart failure.

Cocoa flavanols reduce N-terminal pro-B-type natriuretic peptide in patients with chronic heart failure. 27588209 2016 09 02 2017 02 20 2055-5822 3 2 2016 Jun ESC heart failure ESC Heart Fail Cocoa flavanols reduce N-terminal pro-B-type natriuretic peptide in patients with chronic heart failure. 97-106 Poor prognosis in chronic heart failure (HF) is linked to endothelial dysfunction for which there is no specific treatment currently available. Previous studies have shown reproducible (...) improvements in endothelial function with cocoa flavanols, but the clinical benefit of this effect in chronic HF has yet to be determined. Therefore, the aim of this study was to assess the potential therapeutic value of a high dose of cocoa flavanols in patients with chronic HF, by using reductions in N-terminal pro-B-type natriuretic peptide (NT-proBNP) as an index of improved cardiac function. Thirty-two patients with chronic HF, stable on guideline-directed medical therapy, were randomized to consume

ESC heart failure2016 Full Text: Link to full Text with Trip Pro

246. Acute and Chronic Heart Failure

Acute and Chronic Heart Failure 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure | European Heart Journal | Oxford Academic '); } We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Search Account Menu Menu Navbar Search Filter Mobile Microsite Search Term search filter search input Article Navigation Close mobile search (...) navigation Article navigation 14 July 2016 Article Contents Article Navigation 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC Piotr Ponikowski (Chairperson) (Poland) * Corresponding authors: Piotr Ponikowski, Department of Heart Diseases, Wroclaw

European Society of Cardiology2016

247. Cost Effectiveness of Eplerenone for the Treatment of Systolic Heart Failure with Mild Symptoms in Alberta, Canada

Cost Effectiveness of Eplerenone for the Treatment of Systolic Heart Failure with Mild Symptoms in Alberta, Canada 27300508 2016 07 27 2017 01 17 2017 01 17 1179-187X 16 5 2016 Oct American journal of cardiovascular drugs : drugs, devices, and other interventions Am J Cardiovasc Drugs Cost Effectiveness of Eplerenone for the Treatment of Systolic Heart Failure with Mild Symptoms in Alberta, Canada. 365-76 10.1007/s40256-016-0177-0 Eplerenone has been demonstrated as being cost effective (...) for the treatment of patients with systolic heart failure (HF) and mild symptoms in several jurisdictions; however, its cost effectiveness is unknown in the context of Alberta, Canada. We used a discrete-event simulation model to compare costs and outcomes between standard care and standard care plus eplerenone for the treatment of HF with mild symptoms. We used Alberta data (whenever possible) together with a healthcare perspective, a lifetime horizon, and 3 % annual discount rate for analyses. Clinically

Institute of Health Economics2016

248. Age- and sex-related differences in use of guideline-recommended care and mortality among patients with incident heart failure in Denmark

Age- and sex-related differences in use of guideline-recommended care and mortality among patients with incident heart failure in Denmark 27496924 2016 09 20 2016 09 20 1468-2834 45 5 2016 Sep Age and ageing Age Ageing Age- and sex-related differences in use of guideline-recommended care and mortality among patients with incident heart failure in Denmark. 635-42 10.1093/ageing/afw119 data are sparse on age- and sex-related differences in use of guideline-recommended care and subsequent (...) mortality among patients with heart failure (HF). we identified 24,308 incident patients with a verified primary diagnosis of HF recorded during 2003-2010 in the Danish Heart Failure Registry. The registry monitors guideline-recommended processes of care: echocardiography, New York Heart Association Classification, treatment with angiotensin converting enzyme inhibitors/angiotensin II receptor blockers, betablockers, physical training and patient education. older age was associated with lower use

EvidenceUpdates2016

249. Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction.

Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction. Background: Sacubitril-valsartan therapy reduces cardiovascular mortality compared with enalapril therapy in patients with heart failure with reduced ejection fraction. Objective: To evaluate the cost-effectiveness of sacubitril-valsartan versus angiotensin-converting enzyme inhibitor therapy in patients with chronic heart failure. Design: Markov decision model. Data Sources: Clinical (...) trials, observational analyses, reimbursement data from the Centers for Medicare & Medicaid Services, drug pricing databases, and Centers for Disease Control and Prevention life tables. Target Population: Patients at an average age of 64 years, New York Heart Association (NYHA) class II to IV heart failure, and left ventricular ejection fraction of 0.40 or less. Time Horizon: Lifetime. Perspective: Societal. Intervention: Treatment with sacubitril-valsartan or lisinopril. Outcome Measures: Life

Annals of Internal Medicine2016

250. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure.

Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. BACKGROUND: The benefit of an implantable cardioverter-defibrillator (ICD) in patients with symptomatic systolic heart failure caused by coronary artery disease has been well documented. However, the evidence for a benefit of prophylactic ICDs in patients with systolic heart failure that is not due to coronary artery disease has been based primarily on subgroup analyses. The management of heart failure has improved (...) since the landmark ICD trials, and many patients now receive cardiac resynchronization therapy (CRT). METHODS: In a randomized, controlled trial, 556 patients with symptomatic systolic heart failure (left ventricular ejection fraction, ≤35%) not caused by coronary artery disease were assigned to receive an ICD, and 560 patients were assigned to receive usual clinical care (control group). In both groups, 58% of the patients received CRT. The primary outcome of the trial was death from any cause

NEJM2016

251. Correlation between inner strength and health-promoting behaviors in women with heart failure

Correlation between inner strength and health-promoting behaviors in women with heart failure 27757194 2018 11 13 2008-5842 8 8 2016 Aug Electronic physician Electron Physician Correlation between inner strength and health-promoting behaviors in women with heart failure. 2810-2817 Inner strength is a factor for mental health and well-being and, consequently, a dynamic component of holistic healing. Health-promoting behaviors are appropriate activities to improve health status and prevent (...) the progression of the functional defect resulting from heart failure. The present study aimed to determine the correlation between inner strength and health-promoting behaviors in women with heart failure referred to hospitals affiliated with Shahid Beheshti University of Medical Sciences (SBMU) in 2013. In this cross-sectional study, 145 women with hearth failure were selected through convenient sampling from the clients referred to hospitals affiliated with SBMU. The data collection tool included a three

Electronic physician2016 Full Text: Link to full Text with Trip Pro

252. Aliskiren, Enalapril, or Both in Heart Failure.

Aliskiren, Enalapril, or Both in Heart Failure. Aliskiren, Enalapril, or Both in Heart Failure. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27532843 Format MeSH and Other Data E-mail Subject Additional text (...) E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Aug 18;375(7):702. doi: 10.1056/NEJMc1606625. Aliskiren, Enalapril, or Both in Heart Failure. , , . Comment on [N Engl J Med. 2016] [N Engl J Med. 2016] PMID: 27532843 DOI: [Indexed for MEDLINE] Free full text Publication types MeSH terms Substances Full Text Sources Medical PubMed Commons 0 comments How to cite this comment

NEJM2016

253. Aliskiren, Enalapril, or Both in Heart Failure.

Aliskiren, Enalapril, or Both in Heart Failure. Aliskiren, Enalapril, or Both in Heart Failure. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27532844 Format MeSH and Other Data E-mail Subject Additional text (...) E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Aug 18;375(7):701-2. doi: 10.1056/NEJMc1606625#SA1. Aliskiren, Enalapril, or Both in Heart Failure. 1 , 1 , 1 . 1 University of Brasilia, Brasilia, Brazil nevesfar@gmail.com. Comment in [N Engl J Med. 2016] Comment on [N Engl J Med. 2016] PMID: 27532844 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text

NEJM2016 Full Text: Link to full Text with Trip Pro

254. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.

Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. IMPORTANCE: Abnormal cardiac metabolism contributes to the pathophysiology of advanced heart failure with reduced left ventricular ejection fraction (LVEF). Glucagon-like peptide 1 (GLP-1) agonists have shown cardioprotective effects in early clinical studies of patients with advanced heart failure, irrespective of type 2 diabetes status. OBJECTIVE (...) : To test whether therapy with a GLP-1 agonist improves clinical stability following hospitalization for acute heart failure. DESIGN, SETTING, AND PARTICIPANTS: Phase 2, double-blind, placebo-controlled randomized clinical trial of patients with established heart failure and reduced LVEF who were recently hospitalized. Patients were enrolled between August 2013 and March 2015 at 24 US sites. INTERVENTIONS: The GLP-1 agonist liraglutide (n = 154) or placebo (n = 146) via a daily subcutaneous injection

JAMA2016

255. Heart failure epidemiology and novel treatments in Japan: facts and numbers

Heart failure epidemiology and novel treatments in Japan: facts and numbers Heart failure epidemiology and novel treatments in Japan: facts and numbers Masaaki Konishi 1 * , Junichi Ishida 1 , Jochen Springer 1 , Stephan von Haehling 1 , Yoshihiro J. Akashi 2 , Hiroaki Shimokawa 3 and Stefan D. Anker 1 1 Innovative Clinical Trials, Department of Cardiology and Pneumology, University of Göttingen Medical School, Göttingen, Germany; 2 Division of Cardiology, Department of Internal Medicine, St (...) . Marianna University School of Medicine, Kawasaki, Japan; 3 Department of Cardiovascular Medicine,Tohoku University Graduate School of Medicine, Sendai, Japan Abstract Japan has the highest proportion of older people in the world, 25.9% of the population were aged 65 or above in 2014. Although there have been no population-based studies that precisely examined the prevalence of heart failure in Japan, one report estimated the number of Japanese outpatients with left ventricular dysfunction was 979, 000

ESC heart failure2016 Full Text: Link to full Text with Trip Pro

256. Multimorbidity in Heart Failure: Effect on Outcomes

Multimorbidity in Heart Failure: Effect on Outcomes 27348135 2016 07 12 2017 02 20 1532-5415 64 7 2016 Jul Journal of the American Geriatrics Society J Am Geriatr Soc Multimorbidity in Heart Failure: Effect on Outcomes. 1469-74 10.1111/jgs.14206 To investigate the effect of the number and type of comorbid conditions on death and hospitalizations in individuals with incident heart failure (HF). Population-based cohort study. Olmsted County, Minnesota. Olmsted County, Minnesota, residents (...) with incident HF from 2000 to 2010 (mean age 76 ± 14, 56% female) (N = 1,714). The prevalence of 16 chronic conditions obtained at HF diagnosis classified into three groups: cardiovascular (CV) related, other physical, and mental. The mean number of conditions per participant was 2.6 ± 1.5 for CV-related conditions, 1.3 ± 1.1 for other physical conditions, and 0.30 ± 0.61 for mental conditions. After a mean follow-up of 4.2 years, 1,073 deaths and 6,306 hospitalizations had occurred. After adjustment

EvidenceUpdates2016

257. Heart Failure After Myocardial Infarction Is Associated With Increased Risk of Cancer

Heart Failure After Myocardial Infarction Is Associated With Increased Risk of Cancer 27417004 2016 07 15 2017 02 20 1558-3597 68 3 2016 Jul 19 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Heart Failure After Myocardial Infarction Is Associated With Increased Risk of Cancer. 265-71 10.1016/j.jacc.2016.04.053 S0735-1097(16)33130-8 Heart failure (HF) is associated with excess morbidity and mortality for which noncardiac causes are increasingly recognized. The authors (...) previously described an increased risk of cancer among HF patients compared with community controls. This study examined whether HF was associated with an increased risk of subsequent cancer among a homogenous population of first myocardial infarction (MI) survivors. A prospective cohort study was conducted among Olmsted County, Minnesota, residents with incident MI from 2002 to 2010. Patients with prior cancer or HF diagnoses were excluded. A total of 1,081 participants (mean age 64 ± 15 years; 60% male

EvidenceUpdates2016

258. 6-Year Change in High Sensitivity Cardiac Troponin-T and Risk for Subsequent Coronary Heart Disease, Heart Failure and Death

6-Year Change in High Sensitivity Cardiac Troponin-T and Risk for Subsequent Coronary Heart Disease, Heart Failure and Death 27439107 2018 10 01 2018 11 13 2380-6591 1 5 2016 08 01 JAMA cardiology JAMA Cardiol Six-Year Change in High-Sensitivity Cardiac Troponin T and Risk of Subsequent Coronary Heart Disease, Heart Failure, and Death. 519-28 10.1001/jamacardio.2016.0765 High-sensitivity cardiac troponin T (hs-cTnT) is a biomarker of cardiovascular risk and could be approved in the United (...) States for clinical use soon. However, data linking long-term temporal change in hs-cTnT to outcomes are limited, particularly in primary prevention settings. To examine the association of 6-year change in hs-cTnT with incident coronary heart disease (CHD), heart failure (HF), and all-cause mortality. This prospective observational cohort study, performed from January 1, 1990, to December 31, 2011, included 8838 participants with biracial representation from the Atherosclerosis Risk in Communities

JAMA cardiology2016 Full Text: Link to full Text with Trip Pro

259. Popeye’s new spinach: IV iron for heart failure patients with iron deficiency

Popeye’s new spinach: IV iron for heart failure patients with iron deficiency Popeye's new spinach: IV iron for heart failure patients with iron deficiency Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Popeye's new spinach: IV iron for heart failure patients with iron deficiency View/ Open Date 2016-02 Format (...) Metadata Abstract Popeye's new spinach: IV iron for heart failure patients with iron deficiency: Bottom line: IV iron therapy increased 6MWT times and decreased hospitalizations due to worsening HF in patients with iron deficiencies. However, these results are tempered by lack of information on oral iron therapy failure, and significant pharmaceutical company oversight of the study. URI Part of Citation Evidence-Based Practice 19, no. 2 (2016): 4 Collections hosted by hosted by

Evidence Based Practice 2016

260. Accuracy of Point-of-Care B-Line Lung Ultrasound in Comparison to NT-ProBNP for Screening Acute Heart Failure

Accuracy of Point-of-Care B-Line Lung Ultrasound in Comparison to NT-ProBNP for Screening Acute Heart Failure 27689182 2016 10 05 2018 11 13 2509-596X 2 3 2016 Sep Ultrasound international open Ultrasound Int Open Accuracy of Point-of-Care B-Line Lung Ultrasound in Comparison to NT-ProBNP for Screening Acute Heart Failure. E90-2 10.1055/s-0042-108343 The objective of this pilot study was to determine the accuracy of point-of-care B-line lung ultrasound in comparison to NT Pro-BNP for screening (...) acute heart failure. An 8-zone lung ultrasound was performed by experienced sonographers in patients presenting with acute dyspnea in the ED. AHF was determined as the final diagnosis by 2 independent reviewers. Contrary to prior studies, B-line ultrasound in our study was highly specific, but moderately sensitive for identifying patients with AHF. There was a strong association between elevated NT-proBNP levels and an increased number of B-lines. In conclusion, point-of-care lung ultrasound

Ultrasound international open2016 Full Text: Link to full Text with Trip Pro